Acute Myelomonocytic Leukemia

Common Name(s)

Acute Myelomonocytic Leukemia

Description for this condition is not yet available.
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Acute Myelomonocytic Leukemia" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Acute Myelomonocytic Leukemia" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Acute Myelomonocytic Leukemia" returned 54 free, full-text research articles on human participants. First 3 results:

t(9;19)(q22;p13) in Acute Myelomonocytic Leukemia.
 

Author(s): Moeinadin Safavi, Akbar Safaei, Marzieh Hosseini

Journal: Turk J Haematol. 2018 Mar;35(1):89-90.

 

Last Updated: 31 Dec 1969

Go To URL
A Phase I Study of Topotecan, Carboplatin and the PARP Inhibitor Veliparib in Acute Leukemias, Aggressive Myeloproliferative Neoplasms, and Chronic Myelomonocytic Leukemia.
 

Author(s): Keith W Pratz, Michelle A Rudek, Ivana Gojo, Mark R Litzow, Michael A McDevitt, Jiuping Ji, Larry M Karnitz, James G Herman, Robert J Kinders, B Douglas Smith, Steven D Gore, Hetty E Carraway, Margaret M Showel, Douglas E Gladstone, Mark J Levis, Hua-Ling Tsai, Gary Rosner, Alice Chen, Scott H Kaufmann, Judith E Karp

Journal: Clin. Cancer Res.. 2017 Feb;23(4):899-907.

 

The PARP inhibitor veliparib delays DNA repair and potentiates cytotoxicity of multiple classes of chemotherapy drugs, including topoisomerase I inhibitors and platinating agents. This study evaluated veliparib incorporation into leukemia induction therapy using a previously described ...

Last Updated: 31 Dec 1969

Go To URL
Mutations in RIT1 cause Noonan syndrome with possible juvenile myelomonocytic leukemia but are not involved in acute lymphoblastic leukemia.
 

Author(s): Hélène Cavé, Aurélie Caye, Nehla Ghedira, Yline Capri, Nathalie Pouvreau, Natacha Fillot, Aurélien Trimouille, Cédric Vignal, Odile Fenneteau, Yves Alembik, Jean-Luc Alessandri, Patricia Blanchet, Odile Boute, Patrice Bouvagnet, Albert David, Anne Dieux Coeslier, Bérénice Doray, Olivier Dulac, Valérie Drouin-Garraud, Marion Gérard, Delphine Héron, Bertrand Isidor, Didier Lacombe, Stanislas Lyonnet, Laurence Perrin, Marlène Rio, Joëlle Roume, Sylvie Sauvion, Annick Toutain, Catherine Vincent-Delorme, Marjorie Willems, Clarisse Baumann, Alain Verloes

Journal: Eur. J. Hum. Genet.. 2016 08;24(8):1124-31.

 

Noonan syndrome is a heterogeneous autosomal dominant disorder caused by mutations in at least eight genes involved in the RAS/MAPK signaling pathway. Recently, RIT1 (Ras-like without CAAX 1) has been shown to be involved in the pathogenesis of some patients. We report a series of ...

Last Updated: 31 Dec 1969

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Acute Myelomonocytic Leukemia" returned 2 free, full-text review articles on human participants. First 3 results:

Advances in the genetics of high-risk childhood B-progenitor acute lymphoblastic leukemia and juvenile myelomonocytic leukemia: implications for therapy.
 

Author(s): Mignon L Loh, Charles G Mullighan

Journal: Clin. Cancer Res.. 2012 May;18(10):2754-67.

 

Hematologic malignancies of childhood comprise the most common childhood cancers. These neoplasms derive from the pathologic clonal expansion of an abnormal cancer-initiating cell and span a diverse spectrum of phenotypes, including acute lymphoblastic leukemia (ALL), acute myeloid ...

Last Updated: 31 Dec 1969

Go To URL
Gingival hyperplasia complicating acute myelomonocytic leukemia.
 

Author(s): C L Cooper, R Loewen, T Shore

Journal: J Can Dent Assoc. 2000 Feb;66(2):78-9.

 

Many systemic illnesses manifest clinical signs in the oral cavity. A remarkable case of gingival hyperplasia heralding the presence of acute myelomonocytic leukemia (AML FAB-M4) is described. The oral manifestations of acute leukemia are reviewed.

Last Updated: 31 Dec 1969

Go To URL
 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Eltrombopag Olamine in Improving Platelet Recovery in Older Patients With Acute Myeloid Leukemia Undergoing Chemotherapy
 

Status: Recruiting

Condition Summary: Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome; Adult Acute Basophilic Leukemia; Adult Acute Eosinophilic Leukemia; Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Minimally Differentiated Myeloid Leukemia (M0); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloblastic Leukemia With Maturation (M2); Adult Acute Myeloblastic Leukemia Without Maturation (M1); Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Myelomonocytic Leukemia (M4); Adult Erythroleukemia (M6a); Adult Pure Erythroid Leukemia (M6b); Secondary Acute Myeloid Leukemia

 

Last Updated: 17 Apr 2018

Go to URL
CPX-351 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
 

Status: Recruiting

Condition Summary: Adult Acute Erythroid Leukemia (M6); Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Minimally Differentiated Myeloid Leukemia (M0); Adult Acute Monoblastic Leukemia and Acute Monocytic Leukemia (M5); Adult Acute Myeloblastic Leukemia With Maturation (M2); Adult Acute Myeloblastic Leukemia Without Maturation (M1); Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Myelomonocytic Leukemia (M4); de Novo Myelodysplastic Syndromes; Previously Treated Myelodysplastic Syndromes; Recurrent Adult Acute Myeloid Leukemia; Secondary Myelodysplastic Syndromes

 

Last Updated: 7 May 2018

Go to URL
A Phase 1 Study to Evaluate H3B-8800 in Participants With Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia
 

Status: Recruiting

Condition Summary: Myelodysplastic Syndromes; Acute Myeloid Leukemia; Chronic Myelomonocytic Leukemia

 

Last Updated: 1 Aug 2018

Go to URL